Towards a personalized assessment of pancreatic function in diabetes

References

• Zimmet PZ. Diabetes and its drivers: the largest epidemic in human history? Clin Diabetes Endocrinol. 2017;3:1.
   PubMedGoogle Scholar
• Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–787.
   PubMed Web of Science ®Google Scholar
• Ogurtsova K, Da Rocha Fernandes JD, Huang Y, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50.
   PubMed Web of Science ®Google Scholar
• Flannick J, Johansson S, Njolstad PR. Common and rare forms of diabetes mellitus: towards a continuum of diabetes subtypes. Nat Rev Endocrinol. 2016;12: 394–406. Epub 2016/04/16.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. ADA EASD. 2012;35:1364–1379.
   Google Scholar
• Tabak AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215–2221.
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes. 2008;26:77–82.
   Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Abdul-Ghani M. Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care. 2011;34:dc11–s221.
   Web of Science ®Google Scholar
• White MG, Shaw JAM, Taylor R. Type 2 diabetes: the pathologic basis of reversible β-cell dysfunction. Diabetes Care. 2016;39:2080–2088.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117.
   PubMed Web of Science ®Google Scholar
• Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–1624.
   PubMed Web of Science ®Google Scholar
• Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care. 1997;20:785–791.
   PubMed Web of Science ®Google Scholar
• Owora AH. Diagnostic validity and clinical utility of HbA1c tests for type 2 diabetes mellitus. Curr Diabetes Rev. 2016;29:29.
   Google Scholar
• Doi SA, Ward GM. Examination of the fasting and 2-h plasma glucose in the light of impairment in beta-cell function: what does the epidemiological data tell us? Endocrine. 2015;48: 170–178. Epub 2014/06/02.
   PubMed Web of Science ®Google Scholar
• Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose. Where is the evidence? Where is the logic? Diabetes Care. 2004;27:592–595.
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Greeley SA, John PM, Winn AN, et al. The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care. 2011;34:622–627.
   PubMed Web of Science ®Google Scholar
• Naylor RN, John PM, Winn AN, et al. Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014;37:202–209.
   PubMed Web of Science ®Google Scholar
• Rubio-Cabezas O, Hattersley AT, Njolstad PR, et al. ISPAD clinical practice consensus guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes. 2014;15(Suppl 20):47–64. Epub 2014/09/04.
   PubMed Web of Science ®Google Scholar
• Xue Y, Ankala A, Wilcox WR, et al. Solving the molecular diagnostic testing conundrum for Mendelian disorders in the era of next-generation sequencing: single-gene, gene panel, or exome/genome sequencing. Genet Med. 2015;17:444–451.
   PubMed Web of Science ®Google Scholar
• Philippe J, Derhourhi M, Durand E, et al. What is the best NGS enrichment method for the molecular diagnosis of monogenic diabetes and obesity? PLoS One. 2015;10:e0143373.
   PubMed Web of Science ®Google Scholar
• Vaxillaire M, Froguel P. Monogenic diabetes: implementation of translational genomic research towards precision medicine. J Diabetes. 2016;8:782–795. Epub 2016/07/09.
   PubMed Web of Science ®Google Scholar
• Online Mendelian Inheritance in Man. OMIM® world wide web URL. Baltimore, MD: McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University; 2017. Available from: https://omim.org
   Google Scholar
• Martin D, Bellanne-Chantelot C, Deschamps I, et al. Long-term follow-up of oral glucose tolerance test-derived glucose tolerance and insulin secretion and insulin sensitivity indexes in subjects with glucokinase mutations (MODY2). Diabetes Care. 2008;31:1321–1323.
   PubMed Web of Science ®Google Scholar
• Klupa T, Solecka I, Nowak N, et al. The influence of dietary carbohydrate content on glycaemia in patients with glucokinase maturity-onset diabetes of the young. J Int Med Res. 2011;39:2296–2301.
   PubMed Web of Science ®Google Scholar
• Isomaa B, Henricsson M, Lehto M, et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia. 1998;41:467–473.
   PubMed Web of Science ®Google Scholar
• Harries LW, Ellard S, Stride A, et al. Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet. 2006;15:2216–2224.
   PubMed Web of Science ®Google Scholar
• Sovik O, Njolstad P, Folling I, et al. Hyperexcitability to sulphonylurea in MODY3. Diabetologia. 1998 May;41(5):607–608.
   PubMed Web of Science ®Google Scholar
• Pearson ER, Liddell WG, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 2000;17:543–545.
   PubMed Web of Science ®Google Scholar
• Katra B, Klupa T, Skupien J, et al. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients–report of two cases. Diabetes Technol Ther. 2010;12:313–316.
   PubMed Web of Science ®Google Scholar
• Timsit J, Bellanne-Chantelot C, Dubois-Laforgue D, et al. Diagnosis and management of maturity-onset diabetes of the young. Treat Endocrinol. 2005;4:9–18.
   PubMedGoogle Scholar
• Marathe PH, Gao HX, Close KL. American diabetes association standards of medical care in diabetes 2017. J Diabetes. 2017 Jan 10. DOI:10.1111/1753-0407.12524.
   Web of Science ®Google Scholar
• Awa WL, Schober E, Wiegand S, et al. Reclassification of diabetes type in pediatric patients initially classified as type 2 diabetes mellitus: 15 years follow-up using routine data from the German/Austrian DPV database. Diabetes Res Clin Pract. 2011;94:463–467.
   PubMed Web of Science ®Google Scholar
• Thomas ER, Brackenridge A, Kidd J, et al. Diagnosis of monogenic diabetes: 10-year experience in a large multi-ethnic diabetes center. J Diabetes Investig. 2016;7:332–337.
   PubMed Web of Science ®Google Scholar
• Johansson BB, Irgens HU, Molnes J, et al. Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry. Diabetologia. 2016;2:2.
   Google Scholar
• Bosma AR, Rigter T, Weinreich SS, et al. A genetic diagnosis of maturity-onset diabetes of the young (MODY): experiences of patients and family members. Diabet Med. 2015;32:1385–1392.
   PubMed Web of Science ®Google Scholar
• Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016;536:41–47. Epub 2016/07/12.
   PubMed Web of Science ®Google Scholar
• Morris AP, Voight BF, Teslovich TM, et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet. 2012;44:981–990.
   PubMed Web of Science ®Google Scholar
• Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med. 2008;359:2208–2219.
   PubMed Web of Science ®Google Scholar
• Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220–2232.
   PubMed Web of Science ®Google Scholar
• Lango H, Palmer CN, Morris AD, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes. 2008;57:3129–3135.
   PubMed Web of Science ®Google Scholar
• Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. Bmj. 2010;14:b4838.
   Google Scholar
• Buzzetti R, Prudente S, Copetti M, et al. Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications: a position statement of the Italian Society of Diabetology. Nutr Metab Cardiovasc Dis. 2016;26:301–387.
   Google Scholar
• Parker SC, Stitzel ML, Taylor DL, et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A. 2013;110:17921–17926.
   PubMed Web of Science ®Google Scholar
• Pasquali L, Gaulton KJ, Rodriguez-Segui SA, et al. Pancreatic islet enhancer clusters enriched in type 2 diabetes risk-associated variants. Nat Genet. 2014;46:136–143. Epub 2014/01/15.
   PubMed Web of Science ®Google Scholar
• Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science. 2012;337:1190–1195.
   PubMed Web of Science ®Google Scholar
• Billings LK, Florez JC. The genetics of type 2 diabetes: what have we learned from GWAS? Ann N Y Acad Sci. 2010;1212: 59–77. Epub 2010/11/26.
   PubMed Web of Science ®Google Scholar
• Bernstein D, Golson ML, Kaestner KH. Epigenetic control of beta-cell function and failure. Diabetes Res Clin Pract. 2017;123: 24–36. Epub 2016/12/06.
   PubMed Web of Science ®Google Scholar
• Di Gialleonardo V, De Vries EFJ, Di Girolamo M, et al. Imaging of β-cell mass and insulitis in insulin-dependent (type 1) diabetes mellitus. Endocr Rev. 2012;33:892–919.
   PubMed Web of Science ®Google Scholar
• Laurent D, Vinet L, Lamprianou S, et al. Pancreatic beta-cell imaging in humans: fiction or option? Diabetes Obes Metab. 2016;18:6–15. Epub 2015/08/01.
   PubMed Web of Science ®Google Scholar
• Malaisse WJ, Louchami K, Sener A. Noninvasive imaging of pancreatic [beta] cells. Nat Rev Endocrinol. 2009;5:394–400.
   PubMed Web of Science ®Google Scholar
• Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic β-cell mass in European subjects with type 2 diabetes. Diabetes, Obesity and Metabolism. 2008;10:32–42.
   PubMed Web of Science ®Google Scholar
• Guasch-Ferré M, Hruby A, Toledo E, et al. Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis. Diabetes Care. 2016;39:833–846.
   PubMed Web of Science ®Google Scholar
• Würtz P, Mäkinen V-P, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes. 2012;61:1372–1380.
   PubMed Web of Science ®Google Scholar
• Menni C, Fauman E, Erte I, et al. Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach. Diabetes. 2013;62:4270–4276. Epub 2013/07/26.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17:448–453. Epub 2011/03/23.
   PubMed Web of Science ®Google Scholar
• Wang-Sattler R, Yu Z, Herder C, et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol. 2012;8:615. Epub 2012/09/27.
   PubMed Web of Science ®Google Scholar
• Magnusson M, Lewis GD, Ericson U, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J. 2013;34:1982–1989. Epub 2012/12/18.
   PubMed Web of Science ®Google Scholar
• Wurtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation. 2015;131:774–785. Epub 2015/01/13.
   PubMed Web of Science ®Google Scholar
• Cobb J, Gall W, Adam K-P, et al. A novel fasting blood test for insulin resistance and prediabetes. J Diabetes Sci Technol. 2013;7:100–110.
   PubMedGoogle Scholar
• Tripathy D, Cobb JE, Gall W, et al. A novel insulin resistance index to monitor changes in insulin sensitivity and glucose tolerance: the act now study. J Clin Endocrinol Metabolism. 2015;100:1855–1862.
   PubMed Web of Science ®Google Scholar
• Eiden M, Koulman A, Hatunic M, et al. Mechanistic insights revealed by lipid profiling in monogenic insulin resistance syndromes. Genome Med. 2015;7:63. Epub 2015/08/15.
   PubMed Web of Science ®Google Scholar
• Drogan D, Dunn WB, Lin W, et al. Untargeted metabolic profiling identifies altered serum metabolites of type 2 diabetes mellitus in a prospective, nested case control study. Clin Chem. 2015;61:487–497.
   PubMed Web of Science ®Google Scholar
• Carter TC, Rein D, Padberg I, et al. Validation of a metabolite panel for early diagnosis of type 2 diabetes. Metabolism. 2016; 65:1399–1408.
   PubMed Web of Science ®Google Scholar
• Yousri NA, Mook-Kanamori DO, Selim MME-D, et al. A systems view of type 2 diabetes-associated metabolic perturbations in saliva, blood and urine at different timescales of glycaemic control. Diabetologia. 2015;58:1855–1867.
   PubMed Web of Science ®Google Scholar
• Nikiforova VJ, Giesbertz P, Wiemer J, et al. Glyoxylate, a new marker metabolite of type 2 diabetes. J Diabetes Res. 2014;2014:685204. Epub 2014/12/20.
   PubMed Web of Science ®Google Scholar
• Walford GA, Porneala BC, Dauriz M, et al. Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes. Diabetes Care. 2014;37:2508–2514.
   PubMed Web of Science ®Google Scholar
• Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes. 2013;62:639–648.
   PubMed Web of Science ®Google Scholar
• Schulze MB, Hoffmann K. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Response to Chien. 2007;30:e90–e.
   Google Scholar
• Wu T, Xie G, Ni Y, et al. Serum metabolite signatures of type 2 diabetes mellitus complications. J Proteome Res. 2015;14:447–456.
   PubMed Web of Science ®Google Scholar
• Pena MJ, Lambers Heerspink HJ, Hellemons ME, et al. Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. Diabetic Med. 2014;31:1138–1147.
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Faber JH, Malmodin D, et al. Metabolic profiling in maturity-onset diabetes of the young (MODY) and young onset type 2 diabetes fails to detect robust urinary biomarkers. PLoS One. 2012;7:e40962. Epub 2012/08/04.
   PubMed Web of Science ®Google Scholar
• Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20:1193–1198. Epub 2014/09/30.
   PubMed Web of Science ®Google Scholar
• Lee J. Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch Pharm Res. 2013;36: 208–222. Epub 2013/02/12.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Piperi C, Ziakas PD, et al. Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008;28:314–321.
   PubMed Web of Science ®Google Scholar
• Esser N, Legrand-Poels S, Piette J, et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–150.
   PubMed Web of Science ®Google Scholar
• De Souza Bastos A, Graves DT, De Melo Loureiro AP, et al. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J Diabetes Complications. 2016;30:1593–1599. Epub 2016/08/09.
   PubMed Web of Science ®Google Scholar
• Shiny A, Bibin YS, Shanthirani CS, et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: an indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technol Ther. 2014;16:524–530.
   PubMed Web of Science ®Google Scholar
• Pedicino D, Liuzzo G, Trotta F, et al. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res. 2013;2013:184258.
   PubMed Web of Science ®Google Scholar
• Meigs JB, Hu FB, Rifai N, et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. Jama. 2004;291:1978–1986.
   PubMed Web of Science ®Google Scholar
• Martins AR, Nachbar RT, Gorjao R, et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis. 2012;11:30.
   PubMed Web of Science ®Google Scholar
• Abbasi A, Sahlqvist A-S, Lotta L, et al. A systematic review of biomarkers and risk of incident type 2 diabetes: an overview of epidemiological, prediction and aetiological research literature. PLoS One. 2016;11:e0163721.
   PubMed Web of Science ®Google Scholar
• Fu Z, Gilbert ER, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9:25–53.
   PubMedGoogle Scholar
• Saisho Y, Kou K, Tanaka K, et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J. 2011;58:315–322.
   PubMed Web of Science ®Google Scholar
• Bellin MD, Beilman GJ, Dunn TB, et al. Islet autotransplantation to preserve beta cell mass in selected patients with chronic pancreatitis and diabetes mellitus undergoing total pancreatectomy. Pancreas. 2013;42:317–321.
   PubMed Web of Science ®Google Scholar
• Chang CA, Haque WZ, Yoshimatsu G, et al. Monitoring of beta cell replacement outcomes. Panminerva Med. 2016;58:59–71.
   PubMed Web of Science ®Google Scholar
• Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130:837–844. Epub 2014/06/28.
   PubMed Web of Science ®Google Scholar
• Walther G, Obert P, Dutheil F, et al. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction. Cross-Sectional Study. Arterioscler Thromb Vasc Biol. 2015;35:1022-1029.
   Google Scholar
• Buijsse B, Simmons RK, Griffin SJ, et al. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33:46–62. Epub 2011/05/31.
   PubMed Web of Science ®Google Scholar
• Cichosz SL, Johansen MD, Hejlesen O. Toward big data analytics: review of predictive models in management of diabetes and its complications. J Diabetes Sci Technol. 2016;10:27–34.
   Google Scholar
• Echouffo-Tcheugui JB, Dieffenbach SD, Kengne AP. Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review. Diabetes Res Clin Pract. 2013;101:255–269. Epub 2013/05/08.
   PubMed Web of Science ®Google Scholar
• Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003;26:725–731.
   PubMed Web of Science ®Google Scholar
• Schulze MB, Hoffmann K, Boeing H, et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care. 2007;30:510–515.
   PubMed Web of Science ®Google Scholar
• Bertsimas D, Kallus N, Weinstein AM, et al. Personalized diabetes management using electronic medical records. Diabetes Care. 2016;40:210-217.
   PubMed Web of Science ®Google Scholar
• Watkins SM, Rowe MW, Kolberg JA, et al. Biomarker models as surrogates for the disposition index in the insulin resistance atherosclerosis study. Diabet Med. 2012;29:1399–1406. Epub 2012/03/15.
   PubMed Web of Science ®Google Scholar
• Kolberg JA, Jorgensen T, Gerwien RW, et al. Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care. 2009;32:1207–1212. Epub 2009/07/01.
   PubMed Web of Science ®Google Scholar
• Urdea M, Kolberg J, Wilber J, et al. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). J Diabetes Sci Tech. 2009;3:748–755.
   PubMedGoogle Scholar
• Shafizadeh TB, Moler EJ, Kolberg JA, et al. Comparison of accuracy of diabetes risk score and components of the metabolic syndrome in assessing risk of incident type 2 diabetes in Inter99 cohort. PLoS One. 2011;6:e22863. Epub 2011/08/11.
   PubMed Web of Science ®Google Scholar
• Cichosz SL, Johansen MD, Knudsen ST, et al. A classification model for predicting eye disease in newly diagnosed people with type 2 diabetes. Diabetes Res Clin Pract. 2015;108:210–215.
   PubMed Web of Science ®Google Scholar
• Aspinall PA, Kinnear PR, Duncan LJ, et al. Prediction of diabetic retinopathy from clinical variables and color vision data. Diabetes Care. 1983;6:144–148.
   PubMed Web of Science ®Google Scholar
• Boyko EJ, Ahroni JH, Cohen V, et al. Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care. 2006;29:1202–1207.
   PubMed Web of Science ®Google Scholar
• Monteiro-Soares M, Dinis-Ribeiro M. External validation and optimisation of a model for predicting foot ulcers in patients with diabetes. Diabetologia. 2010;53:1525–1533.
   PubMed Web of Science ®Google Scholar
• Lin CH, Chang YC, Chuang LM. Early detection of diabetic kidney disease: present limitations and future perspectives. World J Diabetes. 2016;7: 290–301. Epub 2016/08/16.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Gallo M, Candido R, et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med. 2014;129.
   PubMedGoogle Scholar
• Schwartz SS, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the beta-cell-centric classification schema. Diabetes Care. 2016;39:179–186. Epub 2016/01/23.
   PubMed Web of Science ®Google Scholar
• Cerf ME. Beta cell dynamics: beta cell replenishment, beta cell compensation and diabetes. Endocrine. 2013;44:303–311.
   PubMed Web of Science ®Google Scholar
• Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest. 2006;116:1802–1812.
   PubMed Web of Science ®Google Scholar
• Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. 2002;51:S455–61.
   PubMed Web of Science ®Google Scholar
• Hasnain SZ, Prins JB, McGuckin MA. Oxidative and endoplasmic reticulum stress in beta-cell dysfunction in diabetes. J Mol Endocrinol. 2016;56:15–0232.
   Web of Science ®Google Scholar
• Meyerovich K, Ortis F, Allagnat F, et al. Endoplasmic reticulum stress and the unfolded protein response in pancreatic islet inflammation. J Mol Endocrinol. 2016;57:R1–R17.
   PubMed Web of Science ®Google Scholar
• Lanoix J, Paramithiotis E. Secretory vesicle analysis for discovery of low abundance plasma biomarkers. Expert Opin Med Diagn. 2008;2:475–485.
   PubMedGoogle Scholar
• X-J L, Hayward C, Fong P-Y, et al. A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med. 2013;5:207ra142–207ra142.
   PubMed Web of Science ®Google Scholar
• Neutzsky-Wulff AV, Andreassen KV, Hjuler ST, et al. Future detection and monitoring of diabetes may entail analysis of both beta-cell function and volume: how markers of beta-cell loss may assist. J Transl Med. 2012;10:214. Epub 2012/11/01.
   PubMed Web of Science ®Google Scholar
• El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003;144:4154–4163.
   PubMed Web of Science ®Google Scholar
• Van Der Meulen T, Huising MO. Role of transcription factors in the transdifferentiation of pancreatic islet cells. J Mol Endocrinol. 2015;54: R103–17. Epub 2015/03/21.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee MK. beta-Cell regeneration through the transdifferentiation of pancreatic cells: pancreatic progenitor cells in the pancreas. J Diabetes Investig. 2016;7:286–296. Epub 2016/06/23.
   PubMed Web of Science ®Google Scholar
• Jurczyk A, Bortell R, Alonso LC. Human beta-cell regeneration: progress, hurdles, and controversy. Curr Opin Endocrinol Diabetes Obes. 2014;21:102–108.
   PubMed Web of Science ®Google Scholar
• Thorel F, Nepote V, Avril I, et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature. 2010;464:1149–1154.
   PubMed Web of Science ®Google Scholar
• Collombat P, Xu X, Ravassard P, et al. The ectopic expression of Pax4 in the mouse pancreas converts progenitor cells into alpha and subsequently beta cells. Cell. 2009;138:449–462.
   PubMed Web of Science ®Google Scholar
• Papizan JB, Singer RA, Tschen SI, et al. Nkx2.2 repressor complex regulates islet beta-cell specification and prevents beta-to-alpha-cell reprogramming. Genes Dev. 2011;25:2291–2305.
   PubMed Web of Science ®Google Scholar
• Chera S, Baronnier D, Ghila L, et al. Diabetes recovery by age-dependent conversion of pancreatic delta-cells into insulin producers. Nature. 2014;514:503–507.
   PubMed Web of Science ®Google Scholar
• Habener JF, Stanojevic V. Alpha-cell role in beta-cell generation and regeneration. Islets. 2012;4: 188–198. Epub 2012/08/01.
   PubMed Web of Science ®Google Scholar
• Xu X, D’Hoker J, Stange G, et al. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. Cell. 2008;132:197–207.
   PubMed Web of Science ®Google Scholar
• Kim HS, Hong SH, Oh SH, et al. Activin A, exendin-4, and glucose stimulate differentiation of human pancreatic ductal cells. J Endocrinol. 2013;217:241–252.
   PubMed Web of Science ®Google Scholar
• Hall PA, Lemoine NR. Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J Pathol. 1992;166:97–103.
   PubMed Web of Science ®Google Scholar
• Dor Y, Brown J, Martinez OI, et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41–46.
   PubMed Web of Science ®Google Scholar
• Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest. 2007;117:2553–2561.
   PubMed Web of Science ®Google Scholar
• Blaine SA, Ray KC, Anunobi R, et al. Adult pancreatic acinar cells give rise to ducts but not endocrine cells in response to growth factor signaling. Development. 2010;137:2289–2296.
   PubMed Web of Science ®Google Scholar
• Faruki H, Lai-Goldman M. Application of a pharmacogenetic test adoption model to six oncology biomarkers. Per Med. 2010;7:441–450.
   Web of Science ®Google Scholar
• Lai-Goldman M, Faruki H. Abacavir hypersensitivity: a model system for pharmacogenetic test adoption. Genet Med. 2008;10:874–878.
   PubMed Web of Science ®Google Scholar
• Balas EA, Boren SA. Managing clinical knowledge for health care improvement. Yearb Med Inform. 2000;(1):65–70.
   Google Scholar
• Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A(1c) in the management of diabetes. J Diabetes. 2009;1:9–17.
   PubMed Web of Science ®Google Scholar
• Shen B, Hwang J. The clinical utility of precision medicine: properly assessing the value of emerging diagnostic tests. Clin Pharmacol Ther. 2010;88:754-756.
   Web of Science ®Google Scholar
• Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012;15:1162–1171.
   PubMed Web of Science ®Google Scholar
• Frueh FW. Regulation, reimbursement, and the long road of implementation of personalized medicine – a perspective from the United States. Value Health. 2013;16:009.
   Web of Science ®Google Scholar
• Cohen JP, Felix AE. Personalized medicine’s bottleneck: diagnostic test evidence and reimbursement. J Pers Med. 2014;4:163–175.
   PubMedGoogle Scholar
• O’Donnell JC. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research. Value Health. 2013;16:004.
   Web of Science ®Google Scholar
• Conway J. The role of companion diagnostic testing in payer decision making. Am J Manag Care. 2013;19:SP44–5.
   Google Scholar
• Horvath AR, Lord SJ, StJohn A, et al. From biomarkers to medical tests: the changing landscape of test evaluation. Clin Chim Acta. 2014;427:49–57.
   PubMed Web of Science ®Google Scholar
• Santa-Maria CA, Nye L, Mutonga MB, et al. Management of metastatic HER2-positive breast cancer: where are we and where do we go from here? Oncology. 2016;30:148–155.
   PubMed Web of Science ®Google Scholar
• Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–1614.
   PubMed Web of Science ®Google Scholar
• Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46:1111–1118.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. New England J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England J Med. 2008;359:1757–1765.
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626–1634.
   PubMed Web of Science ®Google Scholar